Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | Cytogenetic risk & the impact of daratumumab in myeloma

Luciano Costa • 15 Jun 2020
EHA 2020
Multiple Myeloma Antibodies Daratumumab
APOLLO CANDOR CASTOR

Luciano Costa, MD, PhD, of the UAB School of Medicine, Birmingham, AL, highlights results of a meta-analysis determining the impact of daratumumab in the treatment of multiple myeloma according to cytogenetic risk. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Luciano Costa

Long-term PFS benefit with cilta-cel in standard-risk patients with R/R myeloma in CARTITUDE-4
4:37
Long-term PFS benefit with cilta-cel in standard-risk patients with R/R myeloma in CARTITUDE-4
Luciano Costa • 16 Dec 2025
Initial results from MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R multiple myeloma
3:53
Initial results from MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R multiple myeloma
Luciano Costa • 16 Dec 2025
CA057-003 trial preliminary results: mezigdomide in novel combinations for R/R multiple myeloma
4:04
CA057-003 trial preliminary results: mezigdomide in novel combinations for R/R multiple myeloma
Luciano Costa • 13 Dec 2024
Implications of MRD progression in patients with NDMM treated with quadruplet therapy & autoSCT
4:50
Implications of MRD progression in patients with NDMM treated with quadruplet therapy & autoSCT
Luciano Costa • 13 Dec 2024

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Luciano Costa • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Luciano Costa • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Luciano Costa • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Luciano Costa • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals